myelo-encephalitis

myelo-encephalitis的基本解释

-

[医] 脑脊髓炎

与myelo-encephalitis相关的网络例句 [注：此内容来源于网络，仅供参考]

The main toxicities were myelo-suppression and tardive diarrhea, In conclusion.

毒副反应主要为骨髓抑制、迟发性腹泻。

Subsequent molecular studies discovered that this mutation led to gain-of-function of GATA 2, partly blocking myelo-monocytic differentiation and resulted to acute transformation of CML.

随后的分子生物学研究结果提示该突变导致获得性GATA-2功能增强，部分阻滞了CML髓系祖细胞的分化，为慢粒发生恶性转化提供了重要的分子学证据。

Meta-analysis based on included studies showed that response rate of TP regimen has no statistic significance compared with EP regimen[OR0.83,95%CI(0.63-1.090)],but myelo-suppression such as leucopenia and thrombopenia is more severe; response rate of single topotecan has no statistic significance compared with CE regimen[OR0.59,95%CI(0.22-1.60)]; response rate of TEP regimen has no statistic significance compared with EP regimen [OR1.37, 95%CI(0.82-2.28)], but myelo-suppression such as leucopenia, thrombopenia and anemia is more severe; response rate of IV topotecan has no statistic significance compared with Oral topotecan[OR0.97, 95%CI(0.60-1.57)],so as median time to progression[WMD-2.32, 95%CI(-5.72,1.09)] and median survival time[WMD-1.65, 95%CI(-7.13,3.83)],while neutropenia is more sever in IV topotecan than Oral topotecan.

分析表明，TP方案与EP方案的反应率相似[OR0.83，95％CI(0.63-1.090)]，但具有相对高的致白细胞和血小板下降的骨髓毒性；单药拓扑替康与CE方案的反应率相似[OR0.59，95％CI(0.22-1.60)]；TEP方案与EP方案的反应率相似[OR1.37，95％CI(0.82-2.28)]，TEP方案致化疗后重度白细胞下降、重度血小板下降、重度血红蛋白下降均高于EP方案；口服拓扑替康与静脉滴注拓扑替康的化疗后反应率[OR0.97，95％CI(0.60-1.57)]、中位疾病进展期[WMD-2.32，95％CI(-5.72，1.09)]、中位生存期[WMD-1.65，95％CI(-7.13，3.83)]相似，口服拓扑替康化疗后重度中性粒细胞下降明显低于静脉滴注拓扑替康。

与myelo-encephalitis相关的网络解释 [注：此内容来源于网络，仅供参考]

mydriasis：瞳孔放大,散瞳

mycology 真菌学,霉菌学 | mydriasis 瞳孔放大,散瞳 | myel-;myelo- 骨髓,脊髓

myelitis：骨髓炎, 脊髓炎

myelinopathy 髓鞘质病 | myelitis 骨髓炎 脊髓炎 | myelo 髓

myeloneuritis：脊髓多神经炎

myelomalacia 脊髓软化 | myeloneuritis 脊髓多神经炎 | myelo-opticoneuropathy 脊髓视神经病